Dosing & Uses
Dosage Forms & Strengths
injection solution
- 2mg/mL
- 0.75mg
Percutaneous Coronary Intervention
Continuous infusion 2 mcg/kg/min with another 180 mcg/kg IV bolus 10 minutes after 1st one
Continue infusion for at least 12 hours
Safety & efficacy not established
In clinical trials, incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. Adjust dose to renal function
Percutaneous Coronary Intervention
180 mcg/kg IV, THEN
Continuous infusion 2 mcg/kg/min with another 180 mcg/kg IV bolus 10 minutes after 1st one
Continue infusion for at least 12 hours
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
1-10%
Bleeding (8%)
Hypotension (7%)
Thrombocytopenia (2.3%)
Injection site reaction
<1%
Hypersensitivity
Intracranial hemorrhage
Pulmonary hemorrhage
Thrombocytopenia
GI hemorrhage
Postmarketing Reports
Immune-mediated thrombocytopenia (thought to be caused by antibodies that react with GP IIb/IIIa complex)
Warnings
Contraindications
Hypersensitivity
History of internal bleeding, intracranial hemorrhage or neoplasm, CVA, thrombocytopenia
AV malformation or aneurysm, aortic dissection, severe HTN, acute pericarditis
Other parenteral glycoprotein IIb/IIIa inhibitors
Cautions
Bleeding at the site of arterial sheath placement is the most common complication
Early sheath removal is encouraged while eptifibatide is being infused; prior to removing the sheath, it is recommended that heparin be discontinued for 3-4 hr and an aPTT of <45 seconds or ACT <150 seconds be achieved
Thrombocytopenia: Discontinue if platelet levels <100,000 mm/cu.mm
Pregnancy & Lactation
Pregnancy Category: B
Lactation: excretion in milk unknown; use with caution
Pregnancy Categories
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Pharmacology
Mechanism of Action
Blocks binding of fibrinogen and von Willebrand factor to glycoprotein IIb/IIIa receptor on platelet surface
Pharmacokinetics
Half-life, elimination: 2.5 hr
Onset: 1 hr
Duration: 4 hr
Protein bound: 25%
Vd: 185-260 mL/kg
Metabolites: Deaminated eptifibatide, other more polar metabolites detected in urine, no metabolites detected in plasma
Clearance: 55-58 mL/kg/hr
Excretion: Urine
Administration
IV Incompatibilities
Y-site, additive, syringe: furosemide
IV Compatibilities
Y-site: alteplase, amiodarone, atropine, bivalirudin, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine sulfate, nitroglycerin, verapamil
IV Preparation
Bolus injection: withdraw from 10 mL vial (2 mg/mL; 10, 100 mL)
Infusion: no prep needed; spike 100 ml vial with vented infusion set (0.75 mg/mL; 100 mL)
IV Administration
Bolus: administer undiluted over 1-2 min
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
